|
Kerendia’s HF Impact | Heart Band-Aid
August 8, 2024
|
|
|
|
|
Together with
|
|
|
|
“One of the biggest advances in cardiology is the understanding that heart disease is largely preventable.”
|
|
Dr. Valentin Fuster.
|
|
|
|
Bayer’s nsMRA finerenone (Kerendia) might be on track to becoming a key heart failure treatment, after topline results from the FINEARTS-HF trial showed that finerenone significantly reduces cardiovascular death and HF events among patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).
- Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects.
- Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF.
The Phase III FINEARTS-HF trial gave roughly 6,000 patients with HFmrEF or HFpEF (and LVEF ≥40%) either daily finerenone or a placebo, plus standard-of-care. After 42 months…
- Finerenone drove a significant reduction in cardiovascular death and total HF events , achieving the primary endpoint.
- The trial didn’t expose any new safety signals beyond issues seen in finerenone’s previous studies, which included a risk of hyperkalemia.
Even without publicizing the FINEARTS-HF data, confirmation of its “statistically significant” and “clinically meaningful” impact was enough to earn applause across #CardioTwitter, with many suggesting that finerenone might become the first nsMRA heart failure treatment.
- If that happens, nsMRAs would join a quickly-evolving panel of HFpEF treatments, which first added SGLT2is just a few years ago and could add GLP-1s by next year.
Given nsMRAs’ potential to become a leading HF treatment, and the lack of current options for many HF patients, Bayer is all-in on finerenone.
- The FINEARTS-HF study is part of Bayer’s massive 15k-patient MOONRAKER program, which could establish finerenone’s role across an even wider spectrum of HF patients.
- Add those potential HF treatments with finerenone’s current CKD-based indication, and Bayer forecasts that finerenone’s revenue could jump from $295M in 2023 to $3.3B in the future.
The Takeaway
There’s still a lot we don’t know about the FINEARTS-HF trial, but this topline announcement suggests that finerenone could be on track to be the first nsMRA heart failure treatment. That would be a big deal for the millions of patients with HFmrEF and HFpEF, and for Bayer who could have a blockbuster on its hands.
|
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
Experience the Future of Learning: Medtronic Academy 2.0 is Here!
Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
|
|
The Bunkerhill Blueprint
Advancing an AI solution from concept to clinic used to take years, but Bunkerhill Health is closing that gap at lightning speed. See how Bunkerhill is streamlining AI training, validation, approval, and commercialization to get better AI tools into clinical practice, faster.
|
|
- Heart Band-Aid: A Colorado University Boulder-led team developed a new way to 3D print biomaterials that could lead to “heart Band-Aids” that are strong and flexible enough to be attached to a beating heart or a moving joint, while easily sticking to human tissue. The researchers foresee the new materials used in a range of potential applications, including allowing drug delivery directly to the heart, or to support healing in tissues that have limited capacity to self-repair (like heart and cartilage tissue).
- Wegovy’s HFpEF Setback: Even the hottest drug in the world has setbacks. Novo Nordisk is pulling Wegovy’s FDA submissions for HFpEF, and will reapply next year with data from larger outcomes-focused studies. Previous studies showed that Wegovy had a major impact on HFpEF symptoms and quality-of-life, but they weren’t designed to establish its impact on mortality and HF events. However, deeper analysis of these studies revealed a 69% decrease in CV death or HF hospitalization, making Novo Nordisk confident in future outcomes-focused trials.
- A Core Part of the TAVR Era: Long-term data on Medtronic’s CoreValve TAVR bioprosthesis showed promising clinical and hemodynamic results. The study tracked 882 patients over 12 years, finding that at the end of the period, the patients had relatively low risk of valve dysfunction, failure, and severe hemodynamic deterioration (7.0%, 3.6%, and 1.7%), with a 23.9% risk of cardiovascular death. Notably, the average transaortic gradient decreased significantly post-procedure and remained stable over the follow-up period, highlighting the valve’s durability and effectiveness.
- Novartis’ Entresto Fight: Novartis isn’t allowing a new generic for Entresto to enter the U.S. without a fight. The pharma giant is suing the FDA for approving MSN Laboratories’ generic version of the heart failure drug. The generic includes the same key ingredients as Entresto (sacubitril and valsartan), but its labeling features allegedly incorrect indication and safety information. Entresto is Novartis’ top-selling drug ($6B in 2023), and has been the focus of a series of related generic-blocking lawsuits in recent years.
- AFib’s Skin Link: A Cedars-Sinai-led study found that paroxysmal AFib symptoms are more closely linked to skin sympathetic nerve activity (SKNA) than to heart rhythm alone, potentially revealing why some paroxysmal AFib patients are asymptomatic and others aren’t. In 31 patients, symptomatic AFib episodes showed higher average SKNA (1.260 μV) compared to asymptomatic episodes (1.108 μV) and a higher heart rate (152 bpm vs. 132 bpm). Interestingly, 73% of the symptomatic episodes occurred during normal sinus rhythm.
- CroíValve Adds $16M: Transcatheter tricuspid regurgitation treatment startup CroíValve landed $16M in Series B financing to fund its TANDEM II Early Feasibility Study evaluating the safety and performance of its DUO System. CroíValve and its investors have reason to be optimistic, noting that the DUO system reduced tricuspid regurgitation to moderate or lower levels in 85% of cases in the recent TANDEM I study, with 89% of patients experiencing >15-point KCCQ improvements.
- Liraglutide Improves T2D Risks: In the LEAN-DM trial of 41 T2D patients with no CVD, the diabetes drug liraglutide had a major impact on CVD-related risk factors. Patients taking liraglutide saw improvements in stress myocardial blood flow (1.62 to 1.75 mL/g/min), myocardial perfusion reserve (2.4 to 2.9), and 6-minute walk test performance (488 m to 521 m). Meanwhile, pioglitazone (Takeda’s Actos) didn’t significantly affect any of these metrics.
- Cadrenal & Abbott’s LVAD Alliance: Cadrenal Therapeutics announced that Abbott will support research evaluating whether Cadrenal’s late-stage anticoagulant tecarfarin can improve outcomes in LVAD patients. Abbott’s HeartMate 3 is the only LVAD available in the U.S., explaining its interest in improving LVAD outcomes. Previous studies have shown that tecarfarin improves anticoagulation, particularly in patients on multiple medications and those with impaired renal function, both of which are common in LVAD patients.
- Pediatric Partial Heart: Boston Children’s surgeons performed perhaps the first elective partial heart transplant. Four year-old Jack Mangan had a congenital defect that required multiple procedures, but didn’t fully address his aortic stenosis. After considering a Ross procedure, the family elected for a partial transplant to reduce future operations. The surgeons used an aortic valve from a donor heart that wasn’t viable for a complete transplant, allowing them to replace the boy’s aortic valve with living tissue that will grow with him.
- WATCHMAN Flexes Real-World Safety: A safety assessment of Boston Scientific’s WATCHMAN FLX revealed that its real-world safety outcomes are consistent with the device’s previous PINNACLE FLX study, including a high 97.5% implantation success rate. The key safety endpoint (composite of death, stroke, systemic embolism, and major adverse events requiring surgery) occurred in less than 1% of patients.
- Unequal Follow-up Care: A study of more than 1.6M Medicare patients shows a significant increase in 30-day cardiovascular care follow-up rates between 2010 and 2019 in patients who were hospitalized for acute MI (48.3% to 61.4%) and HF (35.3% to 48.3%). Those are commendable overall results. But among other unsatisfactory disparities, Black patients still had fewer follow-ups than Whites after both AMI (51.9% vs. 59.8%) and HF (39.8% vs. 48.7%) by 2019.
|
|
Tracking Your Post-Treatment Plaque
Tune-in to this on-demand Cleerly webinar where preventative cardiologist John Osborne, MD, PhD, FACC, FNLA explores how to use CTA to track plaque progression and identify residual risk post-treatment.
|
|
Catch up on 2024’s Cardiology Coffee Breaks
Join GE HealthCare on a journey to bridge the gaps to connected cardiovascular care with this season’s Cardiology Coffee Breaks. In the time it takes you to finish your coffee, these Coffee Breaks demonstrate how GE’s integrated solutions empower healthcare organizations to provide precision care, achieve operational efficiency, and enhance patient satisfaction.
|
|
From CPACS to CVIS
Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge by Merative executive brief, and see what makes CVIS such a significant advancement.
|
|
- TeraRecon’s Structural Heart Enhancements: Detecting and addressing mitral valve and LAA conditions can be challenging. Check out TeraRecon’s Structural Heart white paper and discover how improving workflow and pretreatment planning can streamline these processes and potentially improve patient outcomes.
- The Post-Acute Stroke Game Changer: See how Viz Connect solution can optimize your post-acute stroke pathway. The Viz.ai solution allows the cardiology team to promptly receive Neurology referrals to evaluate patients with suspected AFib for cardiac monitoring and reduce their risk of secondary stroke.
- Planning Your Move to The Cloud: There’s a long list of advantages to transitioning your enterprise imaging to the cloud, but you have to plan that move first. This Optum e-book details what health IT and imaging leaders need to know before moving their enterprise medical imaging to the cloud.
- Monebo’s Customers Lead the Way: Monebo’s customers span across the globe, and range from local cardiac monitoring companies to major ECG OEMs. See what they all have in common, and how the Monebo monitoring advantage might help your business.
- Bringing AI Into Echo Workflows: Cardiovascular AI solutions are still far more commonly found in cardiology journal papers than in actual clinical workflows, but that’s changing fast and there’s a lot to learn from AI’s early adopters. Tune into the latest Cardiac Wire Show with Mount Sinai’s Jeffrey Bander, MD and Us2.ai’s Seth Koeppel to see how they launched and expanded their echo AI partnership, and learn how to “adopt echo AI the right way.”
- HeartFlow Uncensored: Dr. Drew’s Health Uncensored did a deep dive on the challenges with traditional heart disease testing and the importance of early diagnoses, while highlighting how HeartFlow’s breakthrough non-invasive tech provides patients clarity and confidence in understanding their heart health.
- Assessing CAD with Circle CVI: Did you know that Circle CVI offers a suite of cardiac CT tools for the assessment of coronary artery disease? See how Circle combines heart function segmentation, automated plaque analysis, CAC scoring, reporting, and viewing in a single dedicated Cardiac CT package.
|
|
|
|
|
